echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > WuXi Junuo: The marketing application for the second indication of CD19 CAR-T was accepted by the State Food and Drug Administration

    WuXi Junuo: The marketing application for the second indication of CD19 CAR-T was accepted by the State Food and Drug Administration

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, WuXi Junuo announced that the China National Medical Products Administration (NMPA) has accepted its CD19-targeting autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product, Benoda® (Sweden).


    The new indication marketing application is based on a single-arm, multi-center, pivotal clinical study (RELIANCE study) B cohort of Benoda® for the treatment of Chinese adult patients with r/r B-cell non-Hodgkin lymphoma.


    Professor Song Yuqin, Chief Physician of the Lymphoma Department of Peking University Cancer Hospital and Director of the Chinese Society of Clinical Oncology, said at the ASH annual meeting: "The data from the RELIANCE study shows that Benoda has demonstrated excellent clinical efficacy and safety in patients with r/r FL.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.